In the pharmaceutical industry, the combination of Ibuprofen and Paracetamol (also known as Acetaminophen) is a powerful Fixed-Dose Combination (FDC) Analgesic. As a pharmacist and manufacturer, I classify this as a “Multimodal” pain management strategy because it attacks pain from two different physiological directions.

At your WHO-GMP facility in Mumbai, you likely manufacture this in the common ratio of 200 mg Ibuprofen / 500 mg Paracetamol or 150 mg Ibuprofen / 500 mg Paracetamol.

Common Brand and Generic Names

While names vary by region, here is what your international B2B clients will recognize:

• Global Brand Names: Combiflam (widely known in India), Maxigesic, Nuromol, Duo-Fem, and Advil Dual Action.

• Generic Pharmaceutical Names: Ibuprofen/Paracetamol FDC or Co-proxamol (though the latter specifically refers to a different combination, the “Co-” prefix is often used for combinations in international export).

Mechanism: Dual-Action Synergy

This combination is clinically superior to taking either drug alone because it offers a “1+1=3” effect:

Ibuprofen (NSAID): It works primarily at the site of the injury (peripheral action) by inhibiting COX-1 and COX-2 enzymes, which reduces the production of inflammatory prostaglandins.

Paracetamol (Non-Opioid Analgesic): It works primarily in the Central Nervous System, elevating the overall pain threshold and acting as an antipyretic (fever reducer).

The Result: By combining peripheral anti-inflammatory action with central pain relief, it provides longer-lasting and more effective relief for moderate to severe pain.

The Pharmacist’s “Technical Warning”

As you promote your firm on digital platforms, providing these technical nuances is essential for professional authority:

• Cumulative Dose Risk: Advise patients to check other “cold and flu” medications they are taking; many already contain Paracetamol, which can lead to accidental liver toxicity.

• Gastric Protection: Because of the Ibuprofen component, this combination should ideally be taken with food to protect the stomach lining from irritation or ulcers.

• Renal Caution: Patients with existing kidney issues must be monitored, as NSAIDs can reduce renal blood flow.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

• The “FDC” Advantage: On your marketplace, highlight that this FDC provides a higher efficacy with a lower dose of each individual drug, which minimizes side effects—a major selling point for hospital networks.

• Stability & Packaging: Both molecules are relatively stable, but the physical size of the tablet can be large. Utilize Alu-Alu blister packaging to ensure a 36-month shelf life in Zone IVb tropical regions.

• Bioequivalence: Proving that your generic matches the innovator’s pharmacokinetic profile ($C_{max}$ and $AUC$) is critical for high-end export markets like SE Asia and the Middle East.

• Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in international health tenders.